LEADER 01045nam--2200373---450- 001 990001463930203316 005 20050705171254.0 035 $a000146393 035 $aUSA01000146393 035 $a(ALEPH)000146393USA01 035 $a000146393 100 $a20040301d1926----km-y0itay0103----ba 101 0 $aeng 102 $aGB 105 $a||||||||001yy 200 1 $aSelected letters$fWilliam Cowper 210 $aLondon$cDent$d1926 215 $aXII, 387 p.$d19 cm 225 2 $aEveryman's library 410 0$12001$aEveryman's library 454 1$12001 461 1$1001-------$12001 700 1$aCOWPER,$bWilliam$0131532 801 0$aIT$bsalbc$gISBD 912 $a990001463930203316 951 $aVII.3.A. 719(II i A 147)$b2085 L.M.$cII i A 959 $aBK 969 $aUMA 979 $aSIAV5$b10$c20040301$lUSA01$h1146 979 $aSIAV5$b10$c20040301$lUSA01$h1146 979 $aPATRY$b90$c20040406$lUSA01$h1742 979 $aCOPAT2$b90$c20050705$lUSA01$h1712 996 $aSelected letters$9886106 997 $aUNISA LEADER 04326nam 22003493a 450 001 9910765829703321 005 20250203235427.0 010 $a9783038976936 010 $a3038976938 024 8 $a10.3390/books978-3-03897-693-6 035 $a(CKB)5400000000000145 035 $a(ScCtBLL)cf081a02-252e-4cfe-8a7e-9ae8a0560c82 035 $a(OCoLC)1105784564 035 $a(EXLCZ)995400000000000145 100 $a20250203i20192019 uu 101 0 $aeng 135 $auru|||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPleiotropic Action of Selenium in the Prevention and Treatment of Cancer, and Related Diseases$fYoucef M. Rustum 210 1$aBasel, Switzerland :$cMDPI,$d2019. 215 $a1 online resource (1 p.) 330 $aGene cloning and sequence has provided the opportunity to identify and characterize the functional role of biomarkers expressed in and on tumor cells and the surrounding microenvironment. Molecular and immunologic heterogeneity of cells in the tumor microenvironment contributes to instability, enhanced angiogenesis, and drug resistance of the tumor cell. Since tumor cells are the ultimate therapeutic targets for drugs and therapy development, the tumor microenvironment that regulates the growth and the delivery of effective drug concentrations to tumor cells is the gatekeeper. Thus, to have a significant impact on the overall survival and cure of patients with advanced cancer, the stabilization of the tumor microenvironment should be the initial treatment, followed by treatment that targets and kills tumor cells. Antiangeogenic therapies hold considerable promise in the treatment of a subset of cancer patients and are reported to have a significant impact on the stabilization of the tumor microenvironment. More recently, selenium-containing molecules, such as se-metylselenocysteine, seleno-L-methionine, and selenized yeast, among others, have been shown to target and modulate biomarkers associated with tumor cells and the tumor microenvironment. The effects are selenium type-, dose-, and schedule-dependent. The pleiotropic actions of selenium are necessary for tumor cell sensitization, and synergy with mechanism-based combinations. This Special Issue is devoted to highlighting evidence for the potential role of specific types, doses, and schedules of selenium alone and in combination with mechanism-based biologic and cytotoxic therapies for the prevention and treatment of cancer and related diseases. The collection of contributions should provide a comprehensive overview of the pharmacology, metabolism, and delineation of the pleiotropic action of different types of selenium molecules, relevant to the use of selenium as a potential modulator of the therapeutic efficacy and toxicity of biologic and cytotoxic therapies for cancer and related diseases. The pleiotropic action of specific types of selenium, doses, and schedule, as a selective and efficacious modulator of genetic, immunologic, and epigenetic biomarkers, should stimulate expanded preclinical research that could ultimately impact the development of new and novel approaches for the treatment of cancer. 610 00$aselenium; methylselenoesters; entosis; anticancer agent; hypoxia; tumor microenvironment; tumor heterogeneity; cancer; cancer stem cells; EMT; cell plasticity; DNA damage and repair; immune evasion; HIF; selenium; glutathione; malignant; viability; DNA damage; ER stress; methylselenocysteine; seleno-l-methionine; clear-cell renal cell carcinoma microRNAs; hypoxia-inducible factor; antitumor activity; selenium-binding protein 1; SBP1; SELENBP1; hSP56; cancer; disease; clear cell renal cell carcinoma; hypoxia-inducible factors (HIFs); selenium; PD-L1; miRNA; VEGF; mTOR inhibitors; selenium species; Se-containing nanoparticles; anticancer; chemotherapeutics; epigenetics; head and neck cancer; selenium; methylseleninic acid; radiation; lipid peroxidation; glutathione; tocopherol; selenium; isoselenourea; melanoma; STAT3; apoptosis 700 $aRustum$b Youcef M$01281244 801 0$bScCtBLL 801 1$bScCtBLL 906 $aBOOK 912 $a9910765829703321 996 $aPleiotropic Action of Selenium in the Prevention and Treatment of Cancer, and Related Diseases$93018417 997 $aUNINA